6. Helicase–Primase Inhibitors: A New Approach to Combat Herpes Simplex Virus and Varicella Zoster Virus

  1. Prof. Dr. Erik De Clercq
  1. Subhajit Biswas1 and
  2. Hugh J. Field2

Published Online: 12 MAY 2011

DOI: 10.1002/9783527635955.ch6

Antiviral Drug Strategies

Antiviral Drug Strategies

How to Cite

Biswas, S. and Field, H. J. (2011) Helicase–Primase Inhibitors: A New Approach to Combat Herpes Simplex Virus and Varicella Zoster Virus, in Antiviral Drug Strategies (ed E. De Clercq), Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany. doi: 10.1002/9783527635955.ch6

Editor Information

  1. Rega Institute Medical Research, University of Leuven, Minderbroedersstraat 10, 3000 Leuven, Belgium

Author Information

  1. 1

    University of Cambridge, Department of Medicine, Level 5, Addenbrooke's Hospital, Hills Road, Cambridge, CB2 0QQ, UK

  2. 2

    University of Cambridge, Department of Veterinary Medicine, Madingley Road, Cambridge, CB 30ES, UK

Publication History

  1. Published Online: 12 MAY 2011
  2. Published Print: 6 APR 2011

Book Series:

  1. Methods and Principles in Medicinal Chemistry

Book Series Editors:

  1. Prof. Dr. Raimund Mannhold4,
  2. Prof. Dr. Hugo Kubinyi5 and
  3. Prof. Dr. Gerd Folkers6

Series Editor Information

  1. 4

    Molecular Drug Research Group, Heinrich-Heine-Universität, Universitätsstrasse 1, 40225 Düsseldorf, Germany

  2. 5

    Donnersbergstrasse 9, 67256 Weisenheim am Sand, Germany

  3. 6

    Collegium Helveticum, STW/ETH Zurich, 8092 Zurich, Switzerland

ISBN Information

Print ISBN: 9783527326969

Online ISBN: 9783527635955



  • cross-resistance;
  • helicase–primase complex;
  • HPI-resistant mutants;
  • latent infection;
  • nucleoside analogues;
  • plaque reduction assay


This chapter contains sections titled:

  • Introduction

  • The Role of Helicase Primase in the Replication of HSV

  • Selective Inhibitors of Helicase Primase as Antiherpesvirus Antivirals

  • HPIs are Effective in Cell Culture and In Vivo

  • Effects of HPIs on the Establishment and Reactivation from Latency

  • HPIs: The Biochemical Basis for the Proposed Mechanism of Action

  • HSV Acquired Resistance to HPIs

  • Patterns of Cross-Resistance

  • Further Insight into Mode of HPI Interaction with the HSV HP Complex from the Study of Resistance Mutations

  • The Frequency and Origin of HPI-Resistance Mutations

  • UL5 Lys356Asn: a Mutation Conferring High Resistance to HPI

  • The Origin of Resistance Mutations at High Frequency

  • Conclusions

  • References